Dr Timothy Coté joins NORD as CMO
This article was originally published in Scrip
Dr Timothy Coté has been appointed chief medical officer of the National Organization for Rare Disorders in the US, having served as director of the Food and Drug Administration's Office of Orphan Products Development between 2007 and May 2011. Dr Coté's new role will be to provide medical guidance in all areas – particularly advocacy and education – to promote fair, compassionate public policies; encourage the development of safe, effective treatments; and increase awareness of rare diseases and the needs of patients and their families.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.